ArticleScientific reports2025
Predicting the potential distribution of Podophyllum hexandrum Royle in the Himalaya under CMIP6 climate projections.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Assessing future invasion risk by Solanum viarum Dunal in Northwestern Himalaya to inform early detection and management.Scientific reports · 2026Article
- Ecological Niche Differentiation and Distribution Dynamics Revealing Climate Change Responses in the Chinese GenusPlants (Basel, Switzerland) · 2026Article
- Habitat suitability and driving factors of the endangered medicinal plantFrontiers in plant science · 2026Article
- Assessing Habitat Suitability and Range Dynamics ofEcology and evolution · 2026Article
- Assessing the impacts of climate change on the potential distribution of the medicinal plantFrontiers in plant science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Podophyllum hexandrum is a globally endangered medicinal plant facing severe survival challenges. In the present study, habitat suitability modelling of P. hexandrum was carried out to identify potentially suitable habitats in the western Himalayas under current and future climatic scenarios using MaxEnt software. Future distribution modelling was carried out using Shared Socioeconomic Pathways; SSP126, SSP370 and SSP585 for the time period 2041-2070. MaxEnt output maps were categorized into four potential habitat suitability classes using threshold < 0.25 as "not suitable" 0.25-0.50 as "least suitable", 0.51-0.75 as "moderately suitable", and > 0.75 as "highly suitable". Furthermore, overlay analysis was used to calculate loss, gain, and no change areas. Centroid migration direction and distance were also calculated. The model revealed that the precipitation amount of the driest month and mean annual air temperature determine the distribution of P. hexandrum. Under future climatic scenarios, the species is predicted to undergo significant changes in its distribution losing 8.12% and 8.25% of its suitable habitats under SSP370 and SSP585 pathways, respectively. Under SSP126 pathway, the species is predicted to gain an area of 1.63%. The species is predicted to shift southeastwards under all climatic scenarios and the distance of centroid migration will increase with an increased climate extremities. Though overlapping of its suitable habitats with Protected Areas plays an important role in conserving its wild populations. The decline in number of individuals due to habitat fragmentation, low rate of natural regeneration or seed germination and prolonged dormancy is still a serious concern. There is an urgent need to frame pertinent conservation and management policies for habitat restoration and reintroduction of this species, therefore, the present study will serve as a baseline in this direction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.